Antibody-directed therapy: Past, present, and future

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 4, 2001, Pages S111-S116

  Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Anti inflammatory; Autoimmunity; Hyperimmune Igs; Immunomodulation; Monoclonal antibody; Polyclonal antibody

Indexed keywords

CYTOKINE; FC RECEPTOR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFERENCE PAPER; DRUG POTENCY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; RECEPTOR BINDING;

ANTIBODIES; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFLAMMATION;

EID: 0034769492     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.117824     Document Type: Article

References (56)

1. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
2. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses
3. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostrate cancer
4. MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up
5. Preparation and evaluation of the rhenium-188-labeled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukemia
6. Phase I/II trial of DEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
7. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
8. Review article: Efficacy of infliximab in Crohn's disease induction and maintenance of remission
9. Anti-TNF alpha: New therapy for Crohn's disease
10. An overview of monoclonal antibody therapy of cancer
11. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
12. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
13. An open-labeled study of high-dose intravenous immunoglobulin in severe childhood asthma
14. Benefits of high-dose IV immunoglobulin in patients with severe steroid-dependent asthma
15. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin
16. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebo-controlled randomized trial
17. Anti-IgE as novel therapy for the treatment of asthma
18. Treatment of allergic asthma with monoclonal anti-IgE antibody
19. Immunoglobulin for preventing respiratory syncytial virus infection
20. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: Reduction in incidence, severity of illness and cost
21. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment
22. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain
23. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations
24. High-avidity autoantibodies to cytokines
25. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIG)
26. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIG)
27. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIG)
28. Therapeutic preparations of normal polyspecific immunoglobulin G (IVIG) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIG involving the Fas apoptotic pathway
29. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
30. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease
31. Intravenous immune serum globulin replacement in hypogammaglobulinemia: A comparison of high versus low dose therapy
32. Increased susceptibility to mycoplasma infection in patients with hypogammaglobulinemia
33. Ureaplasma urealyticum chronic osteomyelitis in a patient with hypogammaglobulinemia
34. Unique susceptibility to mycoplasma infection in patients with antibody deficiency
35. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy of prophylaxis of bacterial infections and reduction of hospitalizations in human inmmnodeficiency virus-infected children
36. The treatment of Kawasaki syndrome with intravenous gamma globulin
37. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
38. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
39. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome
40. Randomized trial of plasma exchange, intravenous gammaglobulin, and combined treatments in Guillain-Barré syndrome
41. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
42. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study
43. Intravenous immunoglobulin treatment in patients with motor neuron syndrome associated with anti-GM1 antibodies: A double-blind, placebo-controlled study
44. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies
45. Pooled intravenous immunoglobulin in the management of systemic vasculitis
46. New treatment strategies for systemic vasculitis: The role of intravenous immune globulin therapy
47. Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses
48. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
49. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results
50. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis
51. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome
52. Intravenous immunoglobulin therapy for toxic shock syndrome
53. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: Case report and review
54. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: Case report and review
55. Necrotizing fasciitis
56. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo